9 – 11 November 2020, virtual event
As they move past the immediate challenge of contributing solutions to deal with the Covid-19 pandemic, pharmaceutical and biotech companies will face a changed world. Despite the many devastating impacts, the crisis represents an opportunity to innovate at a quicker pace, refine growth strategies and build new partnerships. The Financial Times Global Pharma and Biotech Summit brings together industry leaders and experts to share insights and perspectives on the critical issues set to re-shape the sector in the wake of the COVID-19 pandemic.
As a lead sponsor, ICON is pleased to offer senior executives at clients and other third parties, a complimentary pass for this premier digital event supported by the world's best journalism (a saving of GBP 699). Passes / tickets are limited to maximum two per client - to be registered simply complete the short form and we will contact you.
Paul Hudson, CEO, Sanofi
David Loew, CEO, Ipsen
Anthony Fauci, Director of National Institute of Allergy and Infectious Diseases (NIAID)
Roger Connor, President of Global Vaccines, GSK
Richard Hatchett, CEO, Coalition for Epidemic Preparedness and Innovation (CEPI)
Teresa Graham, Head of Product Strategy, Roche
Bertrand Dobson, Chief Digital Officer, Novartis
Marianne De Backer, Head of Pharmaceuticals Business Development and Licensing
Steven Pearson, Founder and President, Institute for Clinical and Economic Review (ICER)
Jose Baselga, Executive Vice President, Research & Development, Oncology
Susanne Schaffert, President, Oncology, Novartis
Libby Driscoll, Vice President of US Neurosciences, Eli Lilly & Company
President, Clinical Research Services
Monday, November, 09, 4:20 PM - 4:45 PM GMT (25 Min)
Presentation and fireside chat with Clive Cookson, Science Editor, Financial Times, on "Decentralised & hybrid trials - models for increased resilience and better outcomes".
Chief Information Officer
Tuesday, November 10, 11:15 AM - 12:05 PM GMT (50 Min)
Panel: How Technology is Transforming R&D
Pharma companies are using technologies to include advances in AI, functional genomics and other innovations to take a patient focused approach, to accelerate the pace of medicines discovery, to reduce the costs of clinical trials and deliver drugs to patients faster. And advances in the use of technology in R&D is receiving a boost with regulators including the FDA releasing guidelines on the use of RWE/RWD, and with their growing acceptance of novel patient-centred and digital endpoints in the approval of new drugs. What are the ways in which AI and big data are making/will make a meaningful impact in R&D, and where is pharma on its AI /data journey? How successful will pharma companies ultimately be in finding new ways to apply AI to big data sets to discover new drugs, given the complexity of the underlying biology?
Tarek Sherif, Co-CEO and Co-Founder, Medidata
Andrew Hopkins, CEO, ExscIentia
Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times
VP, Women's Health
Tuesday, November 10, 5:20 PM - 6:00 PM GMT (40 Min)
Panel: Women's Health
Women’s healthcare has been largely underserved and underfunded, yet there is significant scope for innovation. Issues to include stigma and the challenge of attracting scientists to this specialisation have impeded market growth, yet the market opportunity is significant. Women account for half the global population and they are the leading decision makers in term of family health and healthcare spend. The health and pharma industry are rallying to the cause, and the field of femtech, for instance, has expanded significantly in recent years. As the issue of under representation of women in drug trials hits the headlines, meanwhile, the business of women’s health is gradually moving to the spotlight. What are the emerging opportunities, and how are early pioneers in this market addressing the market?
Per Falk, President, Ferring Pharmaceuticals
Tania Boler, CEO, Elvie
Halle Tecco, CEO Natalist
Moderator: Hannah Kuchler, US Pharma and Biotech Correspondent, Financial Times
Senior Principal, Global Pricing and Market Access
Roundtable: Advanced therapy medicinal products: HTA evaluation and implications for pricing and reimbursement
Moderator: Bob Swann
Are current Health Technology Assessment (HTA) processes fit for purpose for advanced therapy medicinal products (ATMPs)?
An invite-only discussion on: